Read More 7 minute read Pharma Industry News The drug that could dethrone Voxzogo: FDA clears Ascendis Pharma’s navepegritide alfa for achondroplasia FDA approves Ascendis Pharma's navepegritide alfa for achondroplasia, intensifying competition with BioMarin's Voxzogo. Read what this means for the rare disease market. byPallavi MadhirajuMarch 1, 2026